Linvoseltamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Pre-Registration program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma. According to Globaldata, it is involved in 12 clinical trials, of which 8 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Linvoseltamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Linvoseltamab is expected to reach an annual total of $863 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Linvoseltamab Overview

Linvoseltamab (REGN-5458) is under development for the treatment of relapsed or refractory multiple myeloma. It acts by targeting cells expressing B-cell maturation antigen (BCMA) and CD3. The drug candidate is administered through intravenous and/or subcutaneous route. It is a Bi-specific T-cell engager (BiTE)  monoclonal antibody being developed based on VelociGene and VelocImmune platform technology. It was also under development for the treatment of hematologic and solid tumors.

Regeneron Pharmaceuticals Overview

Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

The company reported revenues of (US Dollars) US$12,172.9 million for the fiscal year ended December 2022 (FY2022), a decrease of 24.3% over FY2021. In FY2022, the company’s operating margin was 38.9%, compared to an operating margin of 55.7% in FY2021. In FY2022, the company recorded a net margin of 35.6%, compared to a net margin of 50.2% in FY2021. The company reported revenues of US$3,362.7 million for the third quarter ended September 2023, an increase of 6.5% over the previous quarter.

For a complete picture of Linvoseltamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.